Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Galletti G, Leach BI, Lam L, Tagawa ST. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev. 2017;57:16–27. doi:10.1016/j.ctrv.2017.04.00828527407
   PubMed Web of Science ®Google Scholar
• Avril T, Vauléon E, Chevet E. Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers. Oncogenesis. 2017;6(8):e373. doi:10.1038/oncsis.2017.7228846078
   PubMed Web of Science ®Google Scholar
• Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci. 2001;26:504–510. doi:10.1016/S0968-0004(01)01908-911504627
   PubMed Web of Science ®Google Scholar
• Ni M, Zhang Y, Lee AS. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J. 2011;434(2):181–188. doi:10.1042/BJ2010156921309747
   PubMed Web of Science ®Google Scholar
• Lee AS. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer. 2014;14(4):263–276. doi:10.1038/nrc370124658275
   PubMed Web of Science ®Google Scholar
• Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene. 2013;32(7):805–818. doi:10.1038/onc.2012.13022508478
   PubMed Web of Science ®Google Scholar
• Wang M, Kaufman RJ. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature. 2016;529(7586):326–335. doi:10.1038/nature1704126791723
   PubMed Web of Science ®Google Scholar
• Delie F, Petignat P, Cohen M. GRP78-targeted nanotherapy against castrate-resistant prostate cancer cells expressing membrane GRP78. Target Oncol. 2013;8(4):225–230. doi:10.1007/s11523-012-0234-923090204
   PubMed Web of Science ®Google Scholar
• Mandelin J, Cardó-Vila M, Driessen WH, et al. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci USA. 2015;112(12):3776–3781. doi:10.1073/pnas.150012811225762070
   PubMed Web of Science ®Google Scholar
• Tan SS, Ahmad I, Bennett HL, et al. GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cancer. J Pathol. 2011;223(1):81–87. doi:10.1002/path.279521125667
   PubMed Web of Science ®Google Scholar
• Pootrakul L, Datar RH, Shi SR, et al. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res. 2006;12(20 Pt 1):5987–5993. doi:10.1158/1078-0432.CCR-06-013317062670
   PubMed Web of Science ®Google Scholar
• Bennett HL, Fleming JT, O’Prey J, Ryan KM, Leung HY. Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. Cell Death Dis. 2010;1:e72. doi:10.1038/cddis.2010.5021364676
   PubMed Web of Science ®Google Scholar
• Ferrara F, Staquicini DI, Driessen WHP, et al. Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proc Natl Acad Sci USA. 2016;113(45):12786–12791. doi:10.1073/pnas.161540011327791181
   PubMed Web of Science ®Google Scholar
• Lu T, Yang W, Wang Z, et al. Knockdown of glucose-regulated protein 78/binding immunoglobulin heavy chain protein expression by asymmetric small interfering RNA induces apoptosis in prostate cancer cells and attenuates migratory capability. Mol Med Rep. 2015;11(1):249–256. doi:10.3892/mmr.2014.273725338653
   PubMed Web of Science ®Google Scholar
• Tanimoto R, Sakaguchi M, Abarzua F, et al. Down-regulation of BiP/GRP78 sensitizes resistant prostate cancer cells to gene-therapeutic overexpression of REIC/Dkk-3. Int J Cancer. 2010;126(7):1562–1569. doi:10.1002/ijc.2476419626590
   PubMed Web of Science ®Google Scholar
• Tuschl T, Borkhardt A. Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy. Mol Interv. 2002;2(3):158–167. doi:10.1124/mi.2.3.15814993376
   PubMedGoogle Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432(7014):173–178. doi:10.1038/nature0312115538359
   PubMed Web of Science ®Google Scholar
• Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541–555. doi:10.1038/nrg376325022906
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu G, Zheng H, Chen X. Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities. Biotechnol Adv. 2014;32(4):831–843. doi:10.1016/j.biotechadv.2013.08.02024013011
   PubMed Web of Science ®Google Scholar
• Majumder P, Bhunia S, Bhattacharyya J, Chaudhuri A. Inhibiting tumor growth by targeting liposomally encapsulated CDC20siRNA to tumor vasculature: therapeutic RNA interference. J Control Release. 2014;180:100–108. doi:10.1016/j.jconrel.2014.02.01224556418
   PubMed Web of Science ®Google Scholar
• Chen CW, Yeh MK, Shiau CY, Chiang CH, Lu DW. Efficient downregulation of VEGF in retinal pigment epithelial cells by integrin ligand-labeled liposome-mediated siRNA delivery. Int J Nanomedicine. 2013;8:2613–2627. doi:10.2147/IJN.S3962223901275
   PubMed Web of Science ®Google Scholar
• Li J, Yang Y, Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release. 2012;158(1):108–114. doi:10.1016/j.jconrel.2011.10.02022056915
   PubMed Web of Science ®Google Scholar
• Xu X, Li Z, Zhao X, Keen L, Kong X. Calcium phosphate nanoparticles-based systems for siRNA delivery. Regen Biomater. 2016;3(3):187–195. doi:10.1093/rb/rbw01027252888
   PubMed Web of Science ®Google Scholar
• Tanimoto T, Hori A, Kami M. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(20):1966. doi:10.1056/NEJMoa1011205
   PubMed Web of Science ®Google Scholar
• Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8(1):12–23. doi:10.1038/nrclinonc.2010.13620859283
   PubMed Web of Science ®Google Scholar
• Hrkach J, Von Hoff D, Mukkaram Ali M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012;4(128):128ra39. doi:10.1126/scitranslmed.3003651
   PubMed Web of Science ®Google Scholar
• Huang J, Zhang X, Wu Z, et al. Preparation and biocompatibility evaluation of PEG-PLL/RGD-PEG-DSPE/Phospholipid/CaP nanoparticles. J Biomed Nanotechnol. 2018;14(1):98–113. doi:10.1166/jbn.2018.246029463368
   PubMed Web of Science ®Google Scholar
• Liu Y, Hu Y, Huang L. Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. Biomaterials. 2014;35(9):3027–3034. doi:10.1016/j.biomaterials.2013.12.02224388798
   PubMed Web of Science ®Google Scholar
• Azad AA, Zoubeidi A, Gleave ME, Kn C. Targeting heat shock proteins in metastatic castration-resistant prostate cancer. Nat Rev Urol. 2015;12(1):26–36. doi:10.1038/nrurol.2014.32025512207
   PubMed Web of Science ®Google Scholar
• Roller C, Maddalo D. The molecular chaperone GRP78/BiP in the development of chemoresistance: mechanism and possible treatment. Front Pharmacol. 2013;4:10. doi:10.3389/fphar.2013.0001023403503
   PubMed Web of Science ®Google Scholar
• Cook KL, Clarke R. Role of GRP78 in promoting therapeutic-resistant breast cancer. Future Med Chem. 2015;7(12):1529–1534. doi:10.4155/FMC.15.8026302335
   PubMed Web of Science ®Google Scholar
• Deying W, Feng G, Shumei L, Hui Z, Ming L, Hongqing W. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells. Biosci Rep. 2017;37(2):pii: BSR20160470. doi:10.1042/BSR20160470
   PubMed Web of Science ®Google Scholar
• Gifford JB, Huang W, Zeleniak AE, et al. Expression of GRP78, master regulator of the unfolded protein response, increases chemoresistance in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2016;15(5):1043–1052. doi:10.1158/1535-7163.MCT-15-077426939701
   PubMed Web of Science ®Google Scholar
• Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev. 2007;59(2–3):75–86. doi:10.1016/j.addr.2007.03.00517449137
   PubMed Web of Science ®Google Scholar
• Dahlman JE, Kauffman KJ, Langer R, Anderson DG. Nanotechnology for in vivo targeted siRNA delivery. Adv Genet. 2014;88:37–69. doi:10.1016/B978-0-12-800148-6.00003-125409603
   PubMed Web of Science ®Google Scholar
• Masood F. Polymeric nanoparticles for targeted drug delivery system for cancer therapy. Mater Sci Eng C Mater Biol Appl. 2016;60:569–578. doi:10.1016/j.msec.2015.11.06726706565
   PubMed Web of Science ®Google Scholar
• Miao L, Guo S, Lin CM, Liu Q, Huang L. Nanoformulations for combination or cascade anticancer therapy. Adv Drug Deliv Rev. 2017;115:3–22. doi:10.1016/j.addr.2017.06.00328624477
   PubMed Web of Science ®Google Scholar
• Xiao B, Ma L, Merlin D. Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy. Expert Opin Drug Deliv. 2016 Epub2016 Jul 6.
   Web of Science ®Google Scholar
• Chen CK, Law WC, Aalinkeel R, et al. Biodegradable cationic polymeric nanocapsules for overcoming multidrug resistance and enabling drug–gene co-delivery to cancer cells. Nanoscale. 2014;6:1567–1572. doi:10.1039/c3nr04804g24326457
   PubMed Web of Science ®Google Scholar
• Zhang CG, Yang SD, Zhu WJ, et al. Distinctive polymer micelle designed for siRNA delivery and reversal of GRP78 gene-dependent multidrug resistance. J Biomed Mater Res B Appl Biomater. 2016. doi:10.1002/jbm.b.33748
   Web of Science ®Google Scholar
• Yang X, Iyer AK, Singh A, et al. GRP78 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Sci Rep. 2015;5:8509. doi:10.1038/srep0850925687880
   PubMed Web of Science ®Google Scholar
• Yang H, Ding R, Tong Z, et al. siRNA targeting of GRP78 reverses multidrug resistance in a nude mouse model of dtxlorubicin-resistant human hepatocellular carcinoma. Anticancer Res. 2016;36(6):2675–2682.27272776
   PubMed Web of Science ®Google Scholar